Search Results
Your search for s matches 6982 pages
Showing 1 - 50A Paradigm Shift In Treating Adult AML?
The scientific revolution in determining the genetic basis of cancer is finally bearing fruit in hematologic neoplasms such as acute myeloid leukemia (AML), where over the past decade a number of effective new drugs have expanded our armamentarium and provided effective—and in some cases...
Colorectal Cancer Liver Metastases: Transplant or Resect?
Colorectal metastases isolated to the liver no longer portend a universally fatal outcome. In 2024, the TransMet study1demonstrated that liver transplantation in select patients could be life-saving—thus changing the treatment paradigm—but so can surgical resection when appropriately applied....
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
“Dripping water hollows out stone, not through force but through persistence.” – Ovid The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing datasets surrounding T-cell–redirecting therapies in relapsed or refractory multiple myeloma....
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic cranial irradiation for patients with SCLC who respond well to first-line therapy to decrease the...
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...
New Four-Biomarker Blood Panel May Improve Early Detection of Pancreatic Cancer
Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, and is most often diagnosed at advanced, unresectable stages, when 5-year survival is just 3%. The results from two retrospective phase II studies investigating blood biomarkers to detect early-stage pancreatic ductal...
AACR Announces Fellows of the AACR Academy Class of 2026
The American Association for Cancer Research (AACR) has announced its newly elected 2026 class of Fellows of the AACR Academy. The Fellows of the AACR Academy was established to honor scientists, clinicians, and physician-scientists whose visionary work has reshaped the landscape of cancer...
Cancer Workforce Challenges Undermine Patient Care and Jeopardize Momentum in Research, Report Finds
The U.S. cancer workforce faces critical challenges that may affect Americans' access to lifesaving cancer care and delay progress in cancer research. A new report from the President's Cancer Panel, Ensuring a Strong Future for America's Cancer Workforce, underscores these key issues—including...
Pembrolizumab Plus Lenvatinib in Recurrent Gynecologic Clear Cell Carcinoma
In a phase II trial (LARA) reported in The Lancet Oncology, Ngoi et al found that the combination of pembrolizumab and lenvatinib was active in patients with recurrent gynecologic clear cell carcinoma. Study Details In the trial, 25 efficacy-eligible patients (27 in safety population) with at least ...
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
Although it’s been widely reported for years that colorectal cancer incidence has been increasing among younger adults under age 50 by between 1% and 2% annually since the mid-1990s,1 two new studies by Kimmie Ng, MD, MPH, Associate Chief of the Division of Gastrointestinal Oncology and Founding...
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings...
Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLL
In the phase III BRUIN CLL-314 trial, response rates were found to be as good with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib as with ibrutinib in both patients with treatment-naive and relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...
HCC: Real-World Patterns of Systemic Therapy, Sequencing, and Survival
A recent retrospective cohort study has described the current treatment patterns, sequencing, and survival outcomes among patients receiving systemic therapy for hepatocellular carcinoma (HCC). The findings, which were published by Lau-Min et al in JAMA Network Open, showed that...
ASTRO Relaunches Research Foundation Under a Single, Focused Identity
The American Society of Radiation Oncology (ASTRO) has announced that they have rebranded their research foundation from the former Radiation Oncology Institute (ROI) to become Speed of Light – The ASTRO Foundation. The intent of the renamed research foundation was to bring both ASTRO and the...
Deb Schrag, MD, MPH, FASCO, Elected 2027–2028 ASCO President
On December 19, 2025, ASCO announced its members had elected Deb Schrag, MD, MPH, FASCO, as President for the 2027–2028 term. Dr. Schrag will begin her term as President-Elect following the conclusion of the 2026 ASCO Annual Meeting. Dr. Schrag, a gastrointestinal medical oncologist, is the George ...
Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC
Monotherapy with a gemcitabine intravesical system (TAR-200; Gem-iDRS) demonstrated high disease-free survival rates in patients with bacillus Calmette-Guérin (BCG)-unresponsive papillary-only high-risk non–muscle-invasive bladder cancer (NMIBC), according to data presented at the 26th Annual...
KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rates compared to radical cystectomy alone in patients with muscle-invasive bladder...
Nikhil Khushalani, MD, on Neoadjuvant and Adjuvant Treatment in CSCC
Nikhil Khushalani, MD, Vice Chair for the Department of Cutaneous Oncology at Moffitt Cancer Center, reviews advances in the adjuvant and neoadjuvant treatment of cutaneous squamous cell carcinoma (CSCC). He discusses the possibility of de-escalating therapy for patients who respond positively to...
Nikhil Khushalani, MD, on Immunotherapy in Advanced Unresectable CSCC
Nikhil Khushalani, MD, Vice Chair for the Department of Cutaneous Oncology at Moffitt Cancer Center, offers his thoughts on the role of immunotherapy in the treatment of advanced cutaneous squamous cell carcinoma (CSCC). Dr. Khushalani discusses the three currently approved immunotherapeutic agents ...
Integrating Mental Health Into Cancer Care: A Community Oncology Imperative
When Julie began chemotherapy for breast cancer, her oncologist adjusted antiemetics weekly and carefully tracked neutrophil counts. Still, no one asked about the panic attacks that kept her awake at night. She told herself this was just part of cancer. It was not until she stopped showing up for...
Eliminating Barriers to Care for Patients With Intellectual and/or Developmental Disabilities
A recent large, retrospective study by Giblon et al has found that individuals with intellectual and/or developmental disabilities face an increased risk of developing cancer, higher symptom burden once they get cancer compared with those without such disabilities, and disparities in accessing...
Validation of Pathology-AI Integration Tool for Risk Stratification in Locally Advanced Colon Cancer Without Chemotherapy
The Combined Analysis of Pathology and Artificial Intelligence (AI; CAPAI) model effectively stratified patients with colon cancer into distinct prognostic groups, identifying nearly half as low-risk, with “favorable” cancer-specific survival outcomes in the absence of adjuvant chemotherapy,...
Toxicity Concerns for PARP Inhibition Given Concurrently With Adjuvant Radiotherapy for Breast Cancer
Rates of radiotherapy-associated adverse events were considerably higher with the concurrent addition of low doses of the PARP inhibitor olaparib compared with radiotherapy alone in patients with inflammatory breast cancer in the adjuvant setting, according to the results of a toxicity analysis...
Renuka Iyer, MD, Named New Chief Medical Officer for NCCN
The National Comprehensive Cancer Network® (NCCN®) has announced the hiring of Renuka Iyer, MD, as the new Chief Medical Officer (CMO) for the organization. Dr. Iyer has a long history of leadership and innovation in oncology. She currently serves as a Professor of Oncology for Roswell Park...
Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups
An exploratory overall survival analysis of the phase III FLAURA2 trial confirmed the overall survival benefit of adding osimertinib to chemotherapy in patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) not previously treated for advanced...
No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer
For the first-line treatment of metastatic esophageal squamous cell carcinoma, the addition of lenvatinib to pembrolizumab and chemotherapy failed to improve overall survival over pembrolizumab plus chemotherapy in the phase III LEAP-014 trial, as reported at the European Society for Medical...
How an Endowed Chair in Cord Blood Research Is Providing New Hope for Patients With High-Risk Leukemia
In 2016, Filippo Milano, MD, PhD, Associate Professor, Translational Science and Therapeutics Division, and Director of the Cord Blood Transplant Program at Fred Hutchinson Cancer Center in Seattle, published the results of his landmark study investigating whether an alternative stem cell donor...
ASCO Election for Open Leadership Positions
The ASCO Nominating Committee has selected 13 distinguished members as candidates for open leadership positions within the Society. President-Elect: Deb Schrag, MD, MPH, FASCO, Memorial Sloan Kettering Cancer Center Dr. Schrag is a gastrointestinal medical oncologist who currently serves as Chair...
Icahn School of Medicine Family Center for Caregiving Launches Website to Further Reach and Broaden Mission
Allison J. Applebaum, PhD, FAPOS, recently announced the launch of the website for the Steven S. Elbaum Family Center for Caregiving at the Icahn School of Medicine at Mount Sinai in New York (www.mountsinai.org/care/palliative-care/elbaum-center-caregiving). Dr. Applebaum is Director of the...
Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC
In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizumab-jsgr plus chemotherapy, a 40% reduction in risk as first-line treatment of advanced squamous...
Proton vs Photon Radiation Therapy for Nonmetastatic Breast Cancer: Focus on Patient Perspective and Satisfaction
Health-related quality-of-life analyses for proton radiation therapy and photon radiation therapy in patients with nonmetastatic breast cancer showed similar impacts on quality of life with both treatments, according to findings from the phase III RadComp consortium trial. Shannon M. MacDonald, MD, ...
Long-Term Survival With Stereotactic Ablative Radiotherapy vs Surgery for Early-Stage NSCLC
With 10 years of follow-up, no significant difference in survival rates was reported between patients who were treated with stereotactic ablative radiotherapy (SABR) or video-assisted thoracoscopic surgery (VATS) for early-stage non–small cell lung cancer (NSCLC). These findings from the revised...
Treatment Advances in Malignant Hematology: 2025 Updates
The pace of therapeutic innovation in hematologic oncology continues to accelerate, moving clinical practice away from broad-spectrum chemotherapy and toward an era of highly personalized, biologically driven treatment. This transformation was the central theme of the 2025 National Comprehensive...
Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC
In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizumab-jsgr plus chemotherapy, a 40% reduction in risk as first-line treatment of advanced squamous...
European Society for Medical Oncology Congress 2025 Meeting Highlights
The European Society for Medical Oncology (ESMO) Congress 2025 in Berlin featured many important trials with the potential to significantly influence clinical practice and improve outcomes for patients with multiple tumor types. These studies highlighted the benefits of novel treatment combination...
Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies
Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for patients with hematologic malignancies, achieving unprecedented responses in some patients, especially those diagnosed with relapsed/refractory B-cell acute lymphocytic leukemia, non-Hodgkin lymphoma, and multiple...
Preliminary Activity of LuPSMA-I&T Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
In an interim analysis of an Australian single-center phase I/II trial (AlphaBet) reported in The Lancet Oncology, Kostos et al found that the combination of lutetium Lu-177–labeled PSMA–I&T (LuPSMA-I&T) and the bone-seeking alpha-emitter radium Ra-223 dichloride (Ra-223) was active in...
ASCO and ONS Issue First Collaborative Guideline on Extravasation
ASCO and the Oncology Nursing Society (ONS) have released their first joint guideline on managing extravasation, an uncommon but potentially life-threatening complication of intravenous antineoplastic therapy.1 Extravasation occurs when an agent with tissue-damaging properties leaks from the...
Reducing the Impact of Climate-Induced Events on Patients and Oncology Staff
Although 2023 made headlines as the hottest year in human history,1 drawing the world closer to breaching the goals outlined in the Paris Agreement to substantially reduce global greenhouse gas emissions to limit global warming to well below 2°C above preindustrial levels (and preferably to...
Multidrug-Resistant Ulcerative Colitis: Response to CD19 CAR T-Cell Therapy in a Single Case
In a letter to the editor published in The New England Journal of Medicine, Markus F. Neurath, MD, of Friedrich-Alexander-University Erlangen–Nuremberg, Erlangen, Germany, and colleagues described the course of treatment in a 21-year-old woman with severe multidrug-resistant ulcerative colitis who...
Safety and Benefit of Radiation Therapy for High-Risk Muscle-Invasive Bladder Cancer
Following cystectomy, patients with muscle-invasive bladder cancer at high risk for recurrence may safely be treated with radiotherapy and may achieve an improvement in locoregional control compared with observation. These findings, which come from the phase III BART trial presented in a plenary...
NCCN Guidelines to Be Integrated Into OpenEvidence's Medical AI Platform
The National Comprehensive Cancer Network (NCCN) has entered into a licensing agreement with OpenEvidence that would make the NCCN Clinical Practice Guidelines in Oncology accessible through OpenEvidence's AI–powered medical platform. “This collaboration will help clinicians access trusted...
Physician-Complementing Artificial Intelligence in Oncology
Use of artificial intelligence (AI) in oncology is advancing rapidly. AI was first used for reading radiology images and analyzing pathology slides. More recently, use of AI has expanded to analyzing large clinical data sets (big data). The next envisioned role for AI in oncology encompasses many ...
Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up of ZUMA-5
As reported in the Journal of Clinical Oncology by Neelapu et al, the 5-year follow-up of the phase II ZUMA-5 trial has shown sustained responses with axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Study Details In the single-arm,...
My 50 Years in Lymphoma: Lessons Learned?
In the 50 years now since my fellowship training, there have been major advances in the diagnosis, staging, prognostic scoring, treatment, and response assessment of lymphomas. To conjure up the future, we must first appreciate the present by understanding how it arose from the past.1 So, a trip in ...
Raajit K. Rampal, MD, PhD, on Managing Anemia and Thrombocytopenia in Patients With Myelofibrosis
Raajit K. Rampal, MD, PhD, Director of the Center for Hematologic Malignancies and the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, discusses management strategies for these two conditions often associated with myelofibrosis. He discusses the role of Janus kinase...
Physician-Complementing Artificial Intelligence in Oncology
Use of artificial intelligence (AI) in oncology is advancing rapidly. AI was first used for reading radiology images and analyzing pathology slides. More recently, use of AI has expanded to analyzing large clinical data sets (big data). The next envisioned role for AI in oncology encompasses many ...
How the Proliferation of Fraudulent Scientific Papers Is Threatening the Integrity of Cancer Research
There is a perception among many scientists that scientific fraud is a rare occurrence, resulting from the actions of a few isolated bad actors. However, an extensive investigation by Reese A.K. Richardson, PhD, postdoctoral fellow at the Center for Science of Science and Innovation, Kellogg School ...
Defying the Odds
In early 2023, I began experiencing serious symptoms that were not easily explained away, including deep vein thrombosis in my left leg, extreme weight loss, bruising, wheezing, and shortness of breath so severe that it was difficult to walk my dog more than a few feet without gasping for air. For...
New Guideline Reflects the Latest Evidence in Support of Postmastectomy Radiation Therapy for Patients With Breast Cancer
A joint task force composed of experts from the American Society of Radiation Oncology (ASTRO), ASCO, and the Society of Surgical Oncology (SSO) has released new guidance for postmastectomy radiation therapy (PMRT) for patients with breast cancer.1 This guideline—which is intended to replace the...
